Merck ’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced results from the pivotal KEYNOTE-010 study, the first
study of its kind to evaluate the potential of an immunotherapy compared
to chemotherapy based on prospective measurement of PD-L1 expression in
patients with advanced non-small cell lung cancer (NSCLC). < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-contact-html fiel...

Source: Merck.com - Product News - December 19, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Keytruda Melanoma MSD pembrolizumab Source Type: news